2026-04-17T17:10:51Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/113412025-10-24T10:29:30Zcom_2072_378070com_2072_378040col_2072_378092

Tobramycin Systemic Absorption in Lung Transplant Recipients Treated With Inhaled Tobramycin: A Cohort Study Sempere González, Abiu Sacanell Lacasa, Judith Campany-Herrero, David Vima Bofarull, Jaume Martin Gomez, M Teresa Sánchez Corujo, Leire Martínez González, Daniel Los-Arcos, Ibai Len, Oscar Gavaldà, Joan Berastegui Garcia, Cristina Bravo Masgoret, Carles Institut Català de la Salut [Sempere A, Los-Arcos I] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Sacanell J, Martínez-González D] Servei de Medicina Intensiva, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Berastegui C, Bravo C] Servei de Trasplantament Pulmonar, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain. [Campany-Herrero D] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Vima J] Servei de Bioquímica Clínica, Laboratoris Clínics, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Martín-Gómez MT] Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Sánchez L] Servei de Cirurgia Toràcica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Len O, Gavaldà J] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERINFEC, ISCIII—CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain Vall d'Hebron Barcelona Hospital Campus Medicaments antibacterians - Efectes secundaris Medicació oral Ronyons - Malalties Trasplantació d'òrgans, teixits, etc. CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Acute Kidney Injury Other subheadings::Other subheadings::Other subheadings::/chemically induced ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Drug Administration Routes::Administration, Inhalation NAMED GROUPS::Persons::Transplant Recipients COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::lesión renal aguda Otros calificadores::Otros calificadores::Otros calificadores::/inducido químicamente TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::vías de administración de medicamentos::administración por inhalación DENOMINACIONES DE GRUPOS::personas::receptores de trasplantes Acute kidney injury; Aminoglycosides; Nephrotoxicity Lesió renal aguda; Aminoglucòsids; Nefrotoxicitat Lesión renal aguda; Aminoglucósidos; Nefrotoxicidad Inhaled tobramycin treatment has been associated with nephrotoxicity in some case reports, but limited data are available about serum levels and its possible systemic absorption in lung transplant recipients (LTR). We conducted a single-center, observational and retrospective study of all adult (>18 years old) LTR treated with inhaled tobramycin for at least 3 days between June 2019 and February 2022. Trough serum levels were collected and >2 μg/mL was considered a high drug level. The primary outcome assessed the presence of detectable trough levels, while the secondary outcome focused on the occurrence of acute kidney injury (AKI) in individuals with detectable trough levels. Thirty-four patients, with a median age of 60 years, were enrolled. The primary indications for treatment were donor bronchial aspirate bacterial isolation (18 patients) and tracheobronchitis (15 patients). In total, 28 patients (82%) exhibited detectable serum levels, with 9 (26%) presenting high levels (>2 μg/mL). Furthermore, 9 patients (26%) developed acute kidney injury during the treatment course. Median trough tobramycin levels were significantly elevated in invasively mechanically ventilated patients compared to non-ventilated individuals (2.5 μg/mL vs. 0.48 μg/mL) (p < 0.001). Inhaled tobramycin administration in LTRs, particularly in those requiring invasive mechanical ventilation, may result in substantial systemic absorption. 2024-04-18T10:22:05Z 2024-04-18T10:22:05Z 2024-03-28 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Sempere A, Los-Arcos I, Sacanell J, Berastegui C, Campany-Herrero D, Vima J, et al. Tobramycin Systemic Absorption in Lung Transplant Recipients Treated With Inhaled Tobramycin: A Cohort Study. Transpl Int. 2024 Mar 28;37:12579. 1432-2277 https://hdl.handle.net/11351/11341 10.3389/ti.2024.12579 38605938 http://hdl.handle.net/11351/11341 eng Transplant International;37 https://doi.org/10.3389/ti.2024.12579 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf Frontiers Media Scientia